论文部分内容阅读
目的观察肾病综合征患者采用卡托普利结合低分子肝素治疗的效果。方法 100例肾病综合征患者,按照不同的治疗方法将其分为甲组与乙组,每组50例。甲组采用常规临床治疗,乙组在甲组基础上采用卡托普利结合低分子肝素治疗。观察比较两组患者治疗前后总胆固醇、血浆白蛋白、24 h尿蛋白定量变化情况以及两组患者临床治疗效果。结果乙组患者临床治疗总有效率为94.0%,显著高于甲组的76.0%,差异具有统计学意义(P<0.05)。两组患者治疗前血浆白蛋白、24 h尿蛋白定量以及总胆固醇比较差异无统计学意义(P>0.05);治疗后,乙组患者的血浆白蛋白、24 h尿蛋白定量以及总胆固醇均优于甲组,差异具有统计学意义(P<0.05)。结论在常规治疗的基础上,对肾病综合征患者采用卡托普利与低分子肝素结合治疗,可以稳定疾病的相关指标,提高患者的临床治疗效果,值得积极推广使用。
Objective To observe the effect of captopril combined with low molecular weight heparin in patients with nephrotic syndrome. Methods One hundred patients with nephrotic syndrome were divided into group A and group B according to different treatment methods, 50 cases in each group. Group A routine clinical treatment, Group B on the basis of Group A captopril combined with low molecular weight heparin. The changes of total cholesterol, plasma albumin, 24 h urinary protein in two groups before and after treatment were observed and compared, and the clinical effects of two groups were compared. Results The total effective rate of clinical treatment in group B was 94.0%, which was significantly higher than that in group A (76.0%), the difference was statistically significant (P <0.05). There were no significant differences in the levels of serum albumin, 24 h urinary protein and total cholesterol before treatment in both groups (P> 0.05). After treatment, the levels of serum albumin, 24 h urinary protein and total cholesterol in group B were excellent In group A, the difference was statistically significant (P <0.05). Conclusion On the basis of routine treatment, the combination of captopril and low molecular weight heparin in patients with nephrotic syndrome can stabilize the relevant indicators of disease and improve the clinical effect of patients, which is worthy of promotion.